Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03098693
Other study ID # R01MH106369-01
Secondary ID R01MH106369
Status Completed
Phase
First received
Last updated
Start date November 21, 2017
Est. completion date September 7, 2020

Study information

Verified date January 2022
Source Medical University of South Carolina
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective observational study of couples in Kisarawe, Tanzania who will be provided an intervention that offers: (1) HIV self-testing kits and pre-test counseling provided at the household, (2) linkage to a counseling and referral center for those who test positive, (3) facilitated enrollment to care and treatment for couples with confirmed HIV infection; and (4) access to pre-exposure prophylaxis for the negative partner in a HIV sero-discordant couple. We will identify HIV sero-discordant couples through the HIV self-testing component, and through identifying discordant couples at the local HIV clinic. HIV sero-discordant couples (N=64 couples) will be administered a baseline, 6- ,12-, and 18-month survey, and the investigators will collect ongoing clinical data from each clinic visit. Biometric data (fingerprint) will be collected at enrollment, and all encounters with the counseling and referral center, and HIV treatment center, to allow linking of utilization of services with survey data.


Description:

The investigators propose to conduct a prospective observational study of cohabitating couples aged 18 years and above in Kisarawe, Tanzania who will be provided: (1) distribution of HIV self-testing kits to cohabitating couples; (2) linkage to confirmatory HIV-testing & counseling for those who test HIV-positive; (3) facilitated enrollment to care and treatment for those couples with confirmed HIV infection; and (4) for HIV serodiscordant couples, access to PrEP for the HIV-negative partner. A baseline survey, and a follow-up survey approximately 2 weeks later and HIV test, will be administered to all couples involved in the self-testing phase of the study. A cohort of 60 to 70 HIV serodiscordant couples will receive a survey at baseline 6-, 12-, and 18-month survey, and the investigators will collect ongoing clinical data from each clinic visit. Biometric data (fingerprint) will be collected at study and intervention encounters to link utilization of services with survey data. The investigators will also enroll serodiscordant couples from patients already receiving care from the Kisarawe Care and Treatment Center (CTC). The specific AIMS evaluate 4 key strategic goals, including: 1. HIV Self-Testing for Stable Couples: (a) assess the acceptability, safety, and factors associated with uptake of HIV self-testing; and (b) determine the proportion of clients testing positive for HIV via self-testing who engage in care. 2. Dyadic Engagement of Sero-Discordant Couples in Care & Prevention: (a) establish the proportion of sero-discordant couples who will enroll in HIV care as a dyad, (b) determine the effect of dyadic care enrollment on HIV care retention and ART adherence, and (c) assess reduction in risk of acquiring HIV infection for the negative partner. 3. Pre-Exposure Prophylaxis (PrEP): (a) establish the proportion and characteristics of HIV negative clients in a sero-discordant relationship who opt to take PrEP, (b) determine how engaging in ARV treatment by the positive partner affects PrEP utilization by the negative partner, and vice versa, and (c) Identify patterns and correlates of risk reduction strategies that couples in care utilize over time (abstinence, ARV for positive partner, PrEP for negative partner, condom use). 4. Operational: (a) determine Dyadic-based Diagnosis, Care, & Prevention (DDCP) program cost and economic efficiency, (b) compare DDCP to clinic-based and mobile VCT with regard to cost and efficiency for testing and linkage to care, and (c) assess the feasibility, acceptability, safety, and utility of using biometric data to track service utilization.


Recruitment information / eligibility

Status Completed
Enrollment 128
Est. completion date September 7, 2020
Est. primary completion date September 7, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: To be eligible for participation in the self-testing cohort, each individual has to be: 1. age 18 years or older (and at least one member of the couple has to be aged 55 years or below), 2. live in the household regularly, 3. have no plans for moving from the area before the follow up period. To be eligible for the prevention and care portion of the study, couples must be: 1. in an HIV sero-discordant relationship, 2. pregnant or breastfeeding women will be allowed to enroll in the study after counseling on the risks and benefits is provided, 3. HIV-negative women who are pregnant or breastfeeding will be allowed to take PrEP after counseling on the risks and benefits is provided. Exclusion Criteria: Couples will not be eligible for enrolled in the sero-discordant sub-cohort if: 1. the HIV-negative member has signs of advanced kidney disease (measured by serum creatinine), 2. the HIV-negative partner has Hepatitis B and markers of poor liver functioning (measured by alanine aminotransferase).

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
HIV Self-Testing
Access to home-based HIV self-testing kits for stable couples.
Immediate Access to ART for HIV infected couple members
Immediate access to ART for HIV infected couple members (per current Tanzanian standard of care).
Access to PrEP for HIV uninfected couple members
Access to PrEP for HIV uninfected couple members.

Locations

Country Name City State
Tanzania Muhimbili University of Health and Allied Programs Dar Es Salaam Pwani

Sponsors (2)

Lead Sponsor Collaborator
Medical University of South Carolina National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

Tanzania, 

Outcome

Type Measure Description Time frame Safety issue
Primary Utilization of HIV Self-Test Kits The proportion of eligible individuals who received an HIV self-test kit who successfully used the kit within two weeks of receiving the test kit. 2 weeks
Primary Sharing of HIV Test Results with Primary Partner The self-reported proportion of study participants who told their primary partner the results of the HIV test generated by the self-test kit. 18 months
Primary Proportion of HIV Sero-discordant Couples who Engage in HIV Care Together Proportion of HIV Sero-discordant Couples who Engage in HIV Care Together 18 months
Primary Adherence to ART Among HIV Infected Members of Sero-discordant Couples Self-reported proportion of doses of ART medication successfully taken on recommended schedule. 18 months
Primary Retention in ART Care Having =2 outpatient visits at least 3 months apart per year 18 months
Primary Uptake of PrEP Proportion of eligible HIV-uninfected cohort members who opt to take PrEP 18 months
Primary Uptake of ARVs Proportion of eligible HIV-infected cohort members who opt to take ART 18 months
Primary Adherence to ART prescription refills among HIV infected members of sero-discordant couples Proportion of ART prescriptions successfully filled based on pharmacy records among HIV-infected members of sero-discordant couples. 18-Months
Primary HIV Viral Load Copies per mL of HIV detected in blood sample. 18-months
Primary Reduction in HIV-related Risk Behaviors Self-reported number of sexual partners. 18 months
Primary Reduction in sex with non-primary sex partners Any self-reported sex with non-primary sexual partner. 18-Months
Primary Reduction in sex acts Self-reported number of vaginal and anal sex acts. 18-months
Primary Reduction in unprotected sex Self-reported proportion of vaginal and anal sex acts in which a condom was used. 18-months
Secondary Program cost per client served Program cost per client served 18 months
See also
  Status Clinical Trial Phase
Recruiting NCT06162897 - Case Management Dyad N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT02528773 - Efficacy of ART to Interrupt HIV Transmission Networks
Active, not recruiting NCT05454839 - Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
Recruiting NCT05322629 - Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women N/A
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Active, not recruiting NCT01790373 - Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence N/A
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Completed NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Phase 4
Active, not recruiting NCT04519970 - Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) N/A
Completed NCT04124536 - Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women N/A
Recruiting NCT05599581 - Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT02758093 - Speed of Processing Training in Adults With HIV N/A
Completed NCT02500446 - Dolutegravir Impact on Residual Replication Phase 4
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2